Fluorodeoxyglucose positron emission tomography, a new technique for increasing the detection rate of coincident thyroid cancer in head and neck oncology.
Clinically occult thyroid cancer is not uncommon and may occur in 1% to 10% of the population Since the first studies on the use of fluorodeoxyglucose positron emission tomography (FDG PET) in clinical oncology some reports have appeared on the detection of occult tumors using this imaging modality. According to these results, the number of patients with head and neck cancer and clinically occult coincident primary tumors at initial presentation may be expected to increase. In two of the four patients presented, the coincident tumor was detected with FDG PET. The possible role of this new imaging technique is discussed in correlation with treatment and clinical outcome.
Stokkel
M P
MP
Department of Nuclear Medicine, Leiden University Medical Center, The Netherlands.
de Klerk
J M
JM
Hordijk
G J
GJ
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000556:secondary; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000000981:diagnostic imaging*; D009382:Neoplasms, Unknown Primary / Q000000981:diagnostic imaging; D010039:Otorhinolaryngologic Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D012680:Sensitivity and Specificity; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed
D001786:Blood Glucose; D019788:Fluorodeoxyglucose F18